# ARHGEF19

## Overview
ARHGEF19 is a gene that encodes the protein Rho guanine nucleotide exchange factor 19, which is a critical regulator of Rho GTPases. These GTPases are pivotal in various cellular processes, including cytoskeletal dynamics, cell migration, and cell cycle progression. The protein is characterized by the presence of several domains, such as the Dbl homology (DH) and pleckstrin homology (PH) domains, which facilitate its interaction with HRAS and other components of the MAPK/ERK signaling pathway. This interaction underscores its role in cancer progression, particularly in small cell lung cancer and hepatocellular carcinoma. Additionally, ARHGEF19 is involved in ciliogenesis, interacting with Daam1 to activate RhoA, which is essential for cilia formation. The gene's expression in various tissues suggests its involvement in multiple physiological processes, and its dysregulation is implicated in diseases such as polycystic kidney disease and spinal muscular atrophy (Corkins2019Divergent; Garofalo2023Preliminary; Wang2020ARHGEF19).

## Structure
ARHGEF19, also known as Rho guanine nucleotide exchange factor 19, is a protein that plays a significant role in the regulation of Rho GTPases, which are involved in various cellular processes. The protein is characterized by the presence of several important domains, including a N-terminal domain, a Dbl homology (DH) domain, a pleckstrin homology (PH) domain, and an SH3 domain. These domains are crucial for its interaction with HRAS, a key component in the MAPK/ERK signaling pathway (Wang2020ARHGEF19).

The DH and PH domains are particularly significant as they are common features in guanine nucleotide exchange factors, facilitating the exchange of GDP for GTP on Rho GTPases, thereby activating them. The interaction of ARHGEF19 with HRAS is facilitated by these domains, which underscores their functional importance in the protein's role in cancer progression (Wang2020ARHGEF19).

The study does not provide detailed information on the primary, secondary, tertiary, or quaternary structure of ARHGEF19, nor does it discuss post-translational modifications or splice variant isoforms. The focus remains on the functional aspects of the protein rather than its detailed molecular structure (Wang2020ARHGEF19).

## Function
ARHGEF19, or Rho guanine nucleotide exchange factor 19, plays a crucial role in the regulation of Rho GTPases, which are essential for various cellular processes such as cytoskeletal dynamics, cell migration, and cell cycle progression. ARHGEF19 facilitates the exchange of GDP for GTP on Rho proteins, thereby activating them to transmit signals that influence cell shape and movement. This protein is typically active in the cytoplasm and is involved in tissue development and maintenance (Corkins2019Divergent).

In the context of ciliogenesis, ARHGEF19 is required for the formation of cilia in mammalian kidney epithelial cells. It interacts with Daam1, a component of the non-canonical Wnt/PCP pathway, and is thought to activate RhoA, which is necessary for ciliogenesis. The loss of ARHGEF19 results in a significant reduction of cilia, indicating its critical role in this process (Corkins2019The; Corkins2019Divergent).

ARHGEF19 is also expressed in various tissues, including the intestine, liver, heart, and kidney in mice, suggesting its involvement in multiple physiological processes. Its role in ciliogenesis and potential interactions with other proteins highlight its importance in cellular and organismal functions (Corkins2019Divergent).

## Clinical Significance
ARHGEF19 has been implicated in several diseases due to its role in cellular signaling pathways. In small cell lung cancer (SCLC), ARHGEF19 is significantly overexpressed, promoting cancer cell proliferation through the MAPK/ERK signaling pathway. This overexpression suggests that ARHGEF19 could serve as a potential diagnostic and therapeutic target for SCLC management (Wang2020ARHGEF19).

In liver cancer, particularly hepatocellular carcinoma (HCC), ARHGEF19 is associated with increased cell proliferation and invasion. The microRNA miR-503 has been identified as an inhibitor of HCC invasion and metastasis by targeting ARHGEF19, indicating its role in cancer progression and metastatic potential (Porras2021Contribution).

ARHGEF19 is also involved in renal ciliogenesis, where its loss leads to a significant reduction in cilia formation. This suggests that alterations in ARHGEF19 could potentially affect kidney development and function, contributing to disorders such as polycystic kidney disease and nephronophthisis (Corkins2019Divergent).

In spinal muscular atrophy (SMA), ARHGEF19 is identified as a treatment-specific gene involved in pathways affected by the disease, highlighting its potential role in muscle development and regeneration (Garofalo2023Preliminary).

## Interactions
ARHGEF19, a Rho guanine nucleotide exchange factor, is involved in several protein interactions that influence cellular signaling pathways. In small cell lung cancer (SCLC), ARHGEF19 interacts with BRAF and HRAS, both of which are key components of the MAPK/ERK signaling pathway. These interactions are crucial for the activation of the pathway, as evidenced by increased levels of phosphorylated MEK1/2 and ERK1/2 upon ARHGEF19 overexpression. The interaction with HRAS is particularly significant, with the DH and PH domains of ARHGEF19 being essential for this binding (Wang2020ARHGEF19).

In the context of renal ciliogenesis, ARHGEF19 associates with Daam1, a component of the non-canonical Wnt/PCP pathway. This interaction is necessary for the activation of RhoA, a process critical for cilia formation. The loss of ARHGEF19 results in a significant reduction of cilia, highlighting its role in this cellular process (Corkins2019The; Corkins2019Divergent). These interactions underscore ARHGEF19's involvement in diverse cellular functions, from cancer progression to ciliogenesis, through its modulation of Rho GTPase activity.


## References


[1. (Porras2021Contribution) Almudena Porras, Celia Sequera, Paloma Bragado, Alvaro Gutierrez-Uzquiza, and Carmen Guerrero. Contribution of c3g and other gefs to liver cancer development and progression. Hepatoma Research, 2021. URL: http://dx.doi.org/10.20517/2394-5079.2021.16, doi:10.20517/2394-5079.2021.16. This article has 0 citations.](https://doi.org/10.20517/2394-5079.2021.16)

2. (Corkins2019The) The Role of the Wnt/PCP Formin Daam1 in Renal Ciliogenesis. This article has 1 citations.

[3. (Corkins2019Divergent) Mark E. Corkins, Vanja Krneta-Stankic, Malgorzata Kloc, Pierre D. McCrea, Andrew B. Gladden, and Rachel K. Miller. Divergent roles of the wnt/pcp formin daam1 in renal ciliogenesis. PLOS ONE, 14(8):e0221698, August 2019. URL: http://dx.doi.org/10.1371/journal.pone.0221698, doi:10.1371/journal.pone.0221698. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0221698)

[4. (Wang2020ARHGEF19) Ziyang Wang, Guangyan Kan, Chunjie Sheng, Chen Yao, Yizhi Mao, and Shuai Chen. Arhgef19 regulates mapk/erk signaling and promotes the progression of small cell lung cancer. Biochemical and Biophysical Research Communications, 533(4):792â€“799, December 2020. URL: http://dx.doi.org/10.1016/j.bbrc.2020.09.085, doi:10.1016/j.bbrc.2020.09.085. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2020.09.085)

[5. (Garofalo2023Preliminary) M. Garofalo, S. Bonanno, S. Marcuzzo, C. Pandini, E. Scarian, F. Dragoni, R. Di Gerlando, M. Bordoni, S. Parravicini, C. Gellera, R. Masson, C. Dosi, R. Zanin, O. Pansarasa, C. Cereda, A. Berardinelli, and S. Gagliardi. Preliminary insights into rna in csf of pediatric sma patients after 6 months of nusinersen. Biology Direct, September 2023. URL: http://dx.doi.org/10.1186/s13062-023-00413-6, doi:10.1186/s13062-023-00413-6. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13062-023-00413-6)